Edition:
United Kingdom

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

6.05USD
23 Apr 2018
Change (% chg)

$-0.18 (-2.89%)
Prev Close
$6.23
Open
$6.26
Day's High
$6.31
Day's Low
$5.99
Volume
49,955
Avg. Vol
90,993
52-wk High
$27.77
52-wk Low
$4.93

Latest Key Developments (Source: Significant Developments)

Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.67.Q4 EARNINGS PER SHARE VIEW $-0.66 -- THOMSON REUTERS I/B/E/S.RA PHARMACEUTICALS - EXPECTS CASH AND CASH EQUIVALENTS AT DEC 31, 2017 AND NET PROCEEDS OF OFFERING TO BE SUFFICIENT TO FUND OPERATIONS THROUGH 2019.  Full Article

Ra Pharmaceuticals Says Public Offering Of 8.40 Mln Common Shares Priced At $6.00/Share
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.40 MILLION COMMON SHARES PRICED AT $6.00PER SHARE.  Full Article

Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.RA PHARMACEUTICALS - INTENDS TO OFFER AND SELL, SUBJECT TO MARKET AND OTHER CONDITIONS, $50 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS.RA PHARMACEUTICALS INC - TOPLINE DATA FROM SECOND CLINICAL INDICATION OF RA101495 SC EXPECTED FIRST HALF OF 2019.  Full Article

Ra Pharmaceuticals posts Q3 loss of $0.68 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Ra Pharmaceuticals Inc :Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.68.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.As of September 30, 2017, Ra Pharma reported total cash and equivalents of $84.1 million​.Company expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018​.  Full Article

Ra Pharmaceuticals files for mixed shelf offering of up to $250 million
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Ra Pharmaceuticals Inc :Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​.  Full Article

Ra Pharmaceuticals reports Q2 loss per share $0.56
Wednesday, 9 Aug 2017 

Aug 10 (Reuters) - Ra Pharmaceuticals Inc :Ra Pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.56.Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.Ra Pharmaceuticals Inc - ‍expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018​.Says no revenue recorded in three months ended June 30, 2017, compared to $3.0 million for same period in 2016.Q2 earnings per share view $-0.52, revenue view $833330.00 -- Thomson Reuters I/B/E/S.  Full Article

RA Pharmaceuticals receives orphan drug designation from FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria
Monday, 31 Jul 2017 

July 31 (Reuters) - RA Pharmaceuticals Inc :RA Pharmaceuticals receives orphan drug designation from the U.S. FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria.RA Pharmaceuticals - ‍encouraged by initial phase 2 data in PNH patients, which showed near-complete inhibition of hemolysis, favorable safety profile​.  Full Article

Ra Pharmaceuticals announces data from phase 2 clinical trial of RA101495
Tuesday, 27 Jun 2017 

June 27 (Reuters) - Ra Pharmaceuticals Inc ::Ra Pharmaceuticals announces initial data from phase 2 clinical trial of RA101495 in Pnh.Ra Pharmaceuticals Inc - rapid declines in LDH and near-complete inhibition of hemolytic activity.Ra Pharmaceuticals Inc - review of initial safety and efficacy data enables opening of Eculizumab switch cohort.Ra Pharmaceuticals Inc - no safety or tolerability concerns identified; no injection site reactions in study.  Full Article

RA Pharmaceuticals Q1 loss per share $0.50
Thursday, 11 May 2017 

May 11 (Reuters) - RA Pharmaceuticals Inc :RA Pharmaceuticals reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.50.Q1 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67

* RA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE